HOME >> MEDICINE >> NEWS
SKCC's Gennadi Glinsky addresses predicting risk in cancer treatment outcome

-up a clinical trial to evaluate the utility of a genetic test measuring the expression profiles of the 11-gene signature as a prognostic and therapy outcome marker.

Gennadi Victor Glinsky, M.D., Ph.D.

Gennadi Victor Glinsky, M.D., Ph.D., is an associate professor at the Sidney Kimmel Cancer Center in San Diego. He is also a consultant for the National Institutes of Health and serves on the National Cancer Institute Review Panels.

Dr. Glinsky holds membership to numerous professional organizations such as the American Association for the Advancement of Science, the American Association for Cancer Research and the Metastasis Research Society. Dr. Glinsky serves as a reviewer for various journals including the Lancet, Journal of Clinical Investigation, Cancer Research, American Journal of Pathology and Oncogene.

Dr. Glinsky earned a doctor of medicine in internal medicine and general pathology. He later received his doctorate in experimental oncology and biochemistry from the Institute of Oncology Problems Academy of Sciences of Ukraine in Kiev.


'"/>

Contact: Jay Jeffcoat
jjeffcoat@skccfoundation.org
858-410-4212
Sidney Kimmel Cancer Center
18-Apr-2005


Page: 1 2

Related medicine news :

1. Asia-European collaboration addresses water management in Indonesia
2. New technology addresses female fertility preservation
3. New research addresses taboos around the impact of rheumatoid arthritis on patients sex lives
4. Friedman addresses UN-sponsored African workshop on E-Governance
5. New handbook addresses lesbian, gay, bisexual and transgender health issues
6. UK addresses funding gap created by US anti-abortion stance
7. New pediatrician workforce policy addresses growing challenges in health care
8. Child magazine editor addresses regions first annual womens and childrens health care conference
9. Why predicting the next influenza pandemic is difficult and how scientists can best prepare
10. Repeat bone mineral density scans do not appear helpful for predicting fractures in most older women
11. HIV measurement appears to be less reliable than thought in predicting loss of CD4 cells

Post Your Comments:
(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... robot lawsuit is nearing its conclusion in Washington ... Bloomberg.com, during closing statements yesterday, an attorney for the ... the company wanted to tie sales and services for ... the training to keep control of surgeons, to keep ...
(Date:5/21/2013)... May 21, 2013 Today, Zane Benefits, ... and FSA accounts. Zane Benefits, which provides comprehensive ... is the leader in defined contribution and ... . , According to Zane Benefits’ website, the Affordable ... signed into law in 2010 and impacts many areas ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Two executives ... Guidance (SBG) will identify which strategies can be most ... high-quality care to the members who are taking them, ... Services, Inc., “How to Manage Specialty Drugs to ... pharmaceuticals are now the main driver for rising prescription ...
(Date:5/21/2013)... 2013 While North Carolina is synonymous ... travel guides. Brunswick Plantation & Golf Resort is synonymous ... access to 27 holes of "Top10" championship golf. ... Carolina, knowing the Top 10 from an ... the overwhelming task of selecting the course to play. ...
(Date:5/21/2013)... Octo Consulting Group, an award-winning ... solutions to the Federal marketplace, has named Tracy ... the newly created role, Denny will be responsible ... firm’s business development function to include business development ... leading strategies to achieve the firm’s strategic growth ...
Breaking Medicine News(10 mins):Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
(Date:5/21/2013)... 2013   Accuray Incorporated (Nasdaq: ... study results involving hundreds of prostate cancer patients ... most widely used form of prostate stereotactic body ... for a median of 5 years, and many ... percent of patients with low-risk and 90.7% of ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... point-of-care blood analysis systems, announced today that ... present at the Stifel Annual Dental & Veterinary Conference ... The conference will be held at Le Parker Meridien ... About Abaxis Abaxis develops, manufactures, ...
(Date:5/21/2013)... DIEGO , May 21, 2013 ... a secondary analysis of its double-blind, randomized, controlled ... is a gene therapy product designed to deliver ... exploratory analysis identified a more robust response to ... prior to treatment relative to those diagnosed 10 ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
Cached News: